A more pleasant way to screen for colon cancer deserves a pleasant website experience. Introducing ShieldCancerScreen.com—your go-to source to learn more about Shield and access valuable resources. Explore how we’re transforming #ColorectalCancer screening with our FDA-approved Shield test today!
Guardant Health
Biotechnology Research
Palo Alto, California 172,587 followers
Conquering Cancer With Data
About us
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.
- Website
-
https://guardanthealth.com/
External link for Guardant Health
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Palo Alto, California
- Type
- Public Company
- Founded
- 2012
Locations
Employees at Guardant Health
Updates
-
Our COSMOS study was published today in Clinical Cancer Research, a journal of the American Association for Cancer Research. The results validate the utility of our Guardant Reveal blood test for predicting colorectal cancer recurrence without the complexity of prior tissue analysis.
COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting CRC Recurrence
investors.guardanthealth.com
-
The Guardant IP legal team, together with leaders from our research and development teams, recently hosted the United States Patent and Trademark Office (USPTO) as part of their Site Experience Education (SEE) Program. The visit provided a valuable platform for us to showcase our groundbreaking work and engage in meaningful dialogue with USPTO officials and we look forward to continued conversations.
-
-
Our Shield blood test is now covered by Medicare and is commercially available in the U.S. as the first FDA-approved blood test for primary #ColorectalCancer (CRC) screening. Our co-CEO AmirAli Talasaz: “From day one, Shield will be covered for more than 45 million Medicare beneficiaries… This is a major step forward in the fight against colorectal cancer and a significant opportunity for Guardant Health.”
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
investors.guardanthealth.com
-
Today we announced our health outcomes study, the CAN-SCREEN model, has been accepted for publication in the Journal of Medical Economics. The study highlights the importance of combining clinically meaningful screening performance with high patient adherence in colorectal cancer screening to optimize CRC-related health outcomes.
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
investors.guardanthealth.com
-
Blood testing has the potential to transform #ColorectalCancer screening, and the FDA approval of our Shield test for people age 45+ at average risk is a major step forward for the 50 million people in the U.S. who are not up to date with screening. Thank you to our clinical and medical partners, to the people who participate in our studies and to our team at Guardant for making this moment possible! More details: https://lnkd.in/expTfVEJ
-
Happy #NationalInternDay to all of our amazing Guardant Interns! Today, we celebrate your dedication and impact. Your hard work and fresh perspectives play a vital role in advancing our mission to conquer cancer with data.
Late post but I wanted to highlight the amazing time we had at the San Francisco Giants game in early July with our fantastic 2024 Guardant Health Interns! ⚾ It was a wonderful opportunity for our interns to bond, network, and enjoy the best stadium in baseball! Here's to building connections and creating lasting memories. #GuardantHealth #Internship2024 #TeamBuilding #SanFranciscoGiants
-
-
Kirk shares his journey with being diagnosed with Stage IV lung cancer and how Guardant360 helped navigate his treatment plan, allowing him to live life fully on his own terms. Explore more of Kirk's story: https://lnkd.in/gg3abyJi
-
Today we announced a major upgrade to our market-leading Guardant360 test. It now covers 10 times more genomic biomarkers, including all guideline-recommended ones across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity. “Guardant360 is the leading liquid biopsy test for patients with advanced cancer, and this major upgrade through our Guardant Infinity smart liquid biopsy platform enables us to give oncologists a much more complete view of cancer,” said co-CEO Helmy Eltoukhy. Read the full release: https://lnkd.in/en5UR-ag
-
Similar pages
Browse jobs
Stock
GH
NASDAQ
20 minutes delay
$29.33
-0.94 (-3.105%)
- Open
- 30.2
- Low
- 28.96
- High
- 30.35
Data from Refinitiv
See more info on